KRAS G12C in bound to quinazoline based switch II pocket (SWIIP) binder

KRAS G12C Drug Development: Discrimination between Switch II Pocket Configurations Using Hydrogen/Deuterium-Exchange Mass Spectrometry.

1.8M sodium phosphate monobasic monohydrate, potassium phosphate dibasic pH6.9

KRAS, covalent inhibitor, quinazoline based, HYDROLASE-HYDROLASE inhibitor complex

binding site for Di-peptide 8ZG B 203 and CYS B 12

binding site for Di-peptide 8ZG C 203 and CYS C 12

binding site for Di-peptide 8ZG D 203 and CYS D 12

binding site for Di-peptide 8ZG E 203 and CYS E 12

binding site for Di-peptide 8ZG F 203 and CYS F 12